Most people assume that when a doctor prescribes a medication, it has been carefully matched to them as an individual. The reality is more complicated — and understanding it could protect your health in a very real way.

The Standard Approach to High Blood Pressure

If your primary care physician finds that your blood pressure is elevated, the first step is typically a recommendation for lifestyle changes: reducing sodium, increasing physical activity, managing stress. But when medication becomes necessary, the standard of care points toward a well-established class of drugs.

The two most common first-line choices are:

• Angiotensin Converting Enzyme (ACE) Inhibitors — drugs like lisinopril or enalapril that relax blood vessels by blocking the enzyme that narrows them
• Angiotensin Receptor Blockers (ARBs) — drugs like losartan or valsartan that work on the same system but through a different mechanism

These medications are prescribed to millions of patients every year. Large clinical trials have demonstrated that they are both safe and effective — for most people. That last phrase is where the story gets important.

The Problem with "Most People"

Clinical studies are designed to evaluate how a drug performs across a large, diverse population. When researchers find that a medication is safe and effective in thousands of study participants, it earns approval and a place in treatment guidelines. That is entirely appropriate.

But you are not a population average. You are one person, with a unique genetic blueprint that determines — among many other things — how your body processes and eliminates drugs.

This process is called drug metabolism, and it is largely controlled by a family of liver enzymes known as the cytochrome P450 (CYP) system. Genes like CYP2D6, CYP3A4, and CYP2C9 encode these enzymes, and variations in these genes are remarkably common. Depending on which variants you carry, you may be a:

• Normal metabolizer — drugs clear your system at the expected rate
• Rapid or ultra-rapid metabolizer — drugs clear too quickly, reducing their effectiveness
• Poor metabolizer — drugs accumulate in your system, raising the risk of toxicity

For a patient who carries a mutation that significantly slows their metabolism of a particular blood pressure drug, the standard prescribed dose does not behave as expected. Instead of reaching a therapeutic level and clearing the body on schedule, the drug accumulates — potentially leading to hypotension (dangerously low blood pressure), dizziness, fainting, or worse.

The Standard Approach to High Cholesterol

A similar dynamic plays out with cholesterol management. If diet and exercise fail to bring elevated cholesterol under control, the next step is almost always a statin — one of the most widely prescribed drug classes in the world. Common examples include simvastatin, rosuvastatin, and pravastatin.

For most patients, statins are safe and effective. But for someone who carries a variant in the SLCO1B1 gene, this standard choice carries a meaningful risk that most physicians never think to check for.

The SLCO1B1 gene encodes a transporter protein in the liver responsible for moving statins out of the bloodstream and into liver cells, where they do their work. When this transporter functions normally, statins are cleared efficiently. When a patient carries a loss-of-function variant in SLCO1B1, statin concentrations in the blood rise significantly — increasing the risk of statin-induced myopathy, a condition involving muscle pain, weakness, and in severe cases, rhabdomyolysis (the breakdown of muscle tissue that can lead to kidney damage).

This is not a rare edge case. The SLCO1B1 521T>C variant is present in a meaningful percentage of the population, and its association with statin-related muscle toxicity is one of the most well-established pharmacogenomic findings in clinical medicine. Yet most patients are never tested for it before their first statin prescription is written.

The Problem with "Trial-and-Error" Medicine is the Errors

Without whole genome sequencing information to guide them, your physician is selecting treatments for blood pressure and high cholesterol based on a best guess at what would be safe and effective for you as an individual. This is not a criticism of your physician — it is simply the reality of how medicine has been practiced for decades.

The standard approach is:

1. Choose the drug that works for most people
2. Start the patient on it
3. Monitor for side effects
4. Adjust or switch if problems arise

This trial-and-error method works reasonably well at the population level. But at the individual level, it means some patients will experience preventable harm before the right medication is found. In the case of blood pressure medications, that harm could be a dangerous drop in blood pressure. In the case of statins, it could be debilitating muscle damage.

What Whole Genome Sequencing Changes

Whole genome sequencing (WGS) reads your complete genetic code — all 3 billion base pairs — in a single test. Unlike targeted panels that check for a predefined list of variants, WGS captures everything, including rare variants that panels might miss.

When your physician has access to your WGS data, the question shifts from "which drug works for most people?" to "which drug will work correctly for you, given how your body is built to process it?"

The identification of gene variants that affect drug metabolism allows for the avoidance of medications that could cause harm — before you ever take the first dose. Your physician can select an alternative agent from a different metabolic pathway, one that your genetic profile indicates you will handle safely and effectively.

This is pharmacogenomics in practice: matching the right drug to the right patient based on their individual biology rather than population averages.

For a detailed look at how the identification of a SLCO1B1 gene variant should influence the selection of statins and blood pressure medications in clinical practice, see the reference document below that shows an actual Sequencing.com result for an actual person (Dr. Mike Vaughn) *HIPAA rights waived

Download PDF

This Is What Direct Primary Care Makes Possible

In a traditional insurance-based practice, a physician managing a panel of 2,000 to 3,000 patients rarely has the time to review genomic data, interpret pharmacogenomic reports, or engage in the kind of individualized analysis this approach requires. Appointments are short, and the pressure to follow standard protocols is high.

At Enlightened Primary Care, our model is built around exactly this kind of medicine. With a patient panel limited to 299 members, we have the time to review your whole genome sequencing results, understand your metabolic profile, and make prescribing decisions that reflect your biology — not a statistical average.

Blood pressure and cholesterol management are just two examples. The same principle applies to antidepressants, pain medications, anticoagulants, and dozens of other drug classes where genetic variants meaningfully affect how your body responds.

The Takeaway

The next time a medication is prescribed to you, it is worth asking: has anyone looked at how my body actually processes this drug?

If the answer is no, you are relying on the same trial-and-error approach that has been standard practice for decades. Whole genome sequencing offers a better path — one where your treatment is informed by your unique genetic makeup from the very beginning.

That is the promise of precision medicine. And it is available to you today.

---

Interested in learning how whole genome sequencing could inform your care at Enlightened Primary Care? Reach out to schedule a conversation with our physicians.